|
Volumn 115, Issue 2, 2012, Pages 284-296
|
A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation
|
Author keywords
[No Author keywords available]
|
Indexed keywords
MIDAZOLAM;
PLACEBO;
REMIMAZOLAM;
AREA UNDER THE CURVE;
ARTICLE;
BODY WEIGHT;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DOSE INCREASE;
DRUG HALF LIFE;
DRUG SAFETY;
HEART OUTPUT;
HUMAN;
IC 50;
NORMAL HUMAN;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SEDATION;
STEADY STATE;
ADULT;
BENZODIAZEPINES;
COMPUTER SIMULATION;
CONSCIOUSNESS;
CONSCIOUSNESS MONITORS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
HYPNOTICS AND SEDATIVES;
INFUSIONS, INTRAVENOUS;
MALE;
MARYLAND;
METABOLIC CLEARANCE RATE;
MIDAZOLAM;
MIDDLE AGED;
MODELS, BIOLOGICAL;
MONTE CARLO METHOD;
PLACEBOS;
TREATMENT OUTCOME;
YOUNG ADULT;
|
EID: 84864413541
PISSN: 00032999
EISSN: None
Source Type: Journal
DOI: 10.1213/ANE.0b013e318241f68a Document Type: Article |
Times cited : (149)
|
References (7)
|